X

Drug Profile

Dengue vaccine - Sanofi

Latest Information Update: 04 Apr 2022

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator sanofi pasteur
Class Attenuated vaccines; Viral vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Dengue

Most Recent Events

03 Oct 2006 sanofi pasteur and the Paediatric Dengue Vaccine Initiative have entered into an agreement to help develop and make readily available a dengue fever vaccine
19 Jan 2005 Aventis Pasteur is now called sanofi pasteur
26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com